On March 14th, the American artificial intelligence (AI) company OpenAI announced the official release of the more powerful next-generation technology GPT-4 to support ChatGPT. The recent explosion of ChatGPT has once again brought all fields related to AI to the forefront. In addition, the epidemic has continuously increased the attention of the AI pharmaceutical industry, and the research and development efforts of many pharmaceutical companies around the world continue to increase. The European version of "Political News Network" recently reported that the next blockbuster drug may be invented by AI. AI designed drugs for treating lymphatic cancer, inflammatory diseases, and motor neuron diseases are currently undergoing human trials. If successful, AI is expected to bring new developments to the pharmaceutical industry, significantly reducing the time required to develop new drugs and helping scientists identify new drug molecules that have not yet been discovered. While pharmaceutical companies are making profits, patients are also able to access more innovative drugs at an unprecedented speed. Can the "whirlwind" caused by AI technology really make the pharmaceutical industry sail? Andrew Hopkins, the founder of Exscientia, one of the first research and development companies to enter the AI pharmaceutical field, has stated that in the future, all drugs will be designed using AI, which is a more effective molecular design approach. The only question is how quickly the industry will adopt this technology. However, the near collapse of clinical AI company Sensyne Health and the failure of IBM supercomputer "Watson" to introduce into the healthcare industry have made people feel that AI is still "too young" in developing new drugs. Currently, everyone's attention is focused on whether AI designed drugs are safe for humans, have expected effects on diseases, and can meet regulatory standards consistent with traditional drugs. With multiple AI designed drugs undergoing human testing, this critical moment may soon come. Exscientia developed the first drug to treat obsessive-compulsive disorder using AI in 2020. This study was interrupted due to failure to meet expected standards, but the company still has clinical trials of an anticancer drug and a drug for treating inflammatory diseases. Schr ö dinger, an American biological research software developer, has a potential lymphoma drug in clinical trials. AI pharmaceutical company Yingsi Intelligent, headquartered in Hong Kong, China, has a drug for treating idiopathic pulmonary fibrosis that is expected to enter the second phase of trials this year. AI pharmaceutical startup "Marginal Genomics" in the United States is currently testing a new treatment for amyotrophic lateral sclerosis. Despite the flourishing of AI pharmaceuticals, Andreas Bendel, a professor of molecular informatics at the University of Cambridge, stated that there are different targets and chemicals in different disease fields, so the approval of AI drugs does not necessarily mean that the prospects for this field are promising. The prerequisite for using AI in drug discovery and development is to use algorithms to search for massive amounts of data, including compound structures, animal studies, and patient information, to determine the target of drugs in the human body, which molecules are most suitable, and how to create new molecules. These massive amounts of data include data from different molecular chemical compositions, research papers, and patient data, among others